Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024 “alfapump implantation significantly improved quality of life and showed similar safety ...
One-year alfapump data from POSEIDON shows safety and strong efficacy profile is maintained at 12 months Patient preference study indicates that US patients have a strong preference for the alfapump ...
Sequana Medical said the company now has five medical centers using its alfapump, the first FDA-approved active implantable medical device to treat liver ascites due to cirrhosis. The new ...
, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dr. Rahul Patel of Icahn School of Medicine at Mount Sinai presented “alfapump®: Totally Implantable Peritoneal Drain Pump with Urinary Bladder Drainage” Ghent, ...
Ghent, Belgium – 16 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...
Ghent, Belgium – 6 June 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results